Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Branislav Vajdic
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 16
- Beta
- -0.79
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -11.15
Financials
Revenue
$0.00-100.0%Net Income
$-5.04M-222.9%EBITDA
$-5.09M-163.5%Free Cash Flow
$-3.59M-159.2%EPS (diluted)
$-0.10-171.4%Shares Outstanding (diluted)
52.77M+74.0%Operating Expenses
$5.09MCash & Debt
$8.72MRevenue by Segment (annual)
$439.11MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-21.02M | $-0.62 |
| 2024 | $0.00 | $-19.45M | $-0.73 |
| 2023 | $0.00 | $-14.64M | $-0.72 |
| 2022 | $0.00 | $-12.96M | $-1.59 |
| 2021 | $0.00 | $-4.43M | $-0.56 |
| 2020 | $0.00 | $-1.07M | $-0.14 |
| 2019 | $0.00 | $-536.0K | $-0.10 |
| 2018 | $399.47M | $42.82M | $1.20 |
| 2017 | $286.78M | $-15.96M | $-0.53 |
| 2016 | $208.33M | $53.44M | $1.91 |
| 2015 | $178.51M | $7.43M | $0.27 |
| 2014 | $166.58M | $-9.79M | $-0.37 |
| 2013 | $129.50M | $-7.32M | $-0.29 |
| 2012 | $111.49M | $-12.20M | $-0.49 |
Valuation
BEAThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
145+107.14%Social Signal Score
Mentions (4)
- Newsbenzinga.com·17h ago·Negative
HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System Medical technology provider HeartBeam, Inc. (NASDAQ:BEAT) received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its at-home cardiac assessment tool.
View source ↗ - Newsbusinesswire.com·22h ago·Neutral
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment.
View source ↗ - Newsbusinesswire.com·14d ago·Neutral
HeartBeam, Inc. Letter to Shareholders SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. Letter to Shareholders.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.09 per share
Typical surprise +5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.10 vs $-0.09miss
- Wed, May 13$-0.12 vs $-0.14beat
- Thu, Mar 12$-0.14 vs $-0.13miss
- Thu, Nov 13$-0.15 vs $-0.16beat
- Wed, Aug 13$-0.15 vs $-0.16beat
- Tue, May 13$-0.18 vs $-0.15miss
Estimates and results for BEAT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BEAT officers and directors.
- Bought
- $1.0m
- Sold
- $1.2m
11 trades
20 trades
- Ferrari Richardbought
- Cruickshank Timbought
- Elfrink Willembought
- Jaff Michael Rbought
- Vajdic Branislavbought
- Ferrari Richardbought
- Eno Robert Paulbought
- Ortigas-wedekind Margabought
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BEAT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.